Glenmark Pharmaceuticals has launched an EMI scheme for cancer patients for the purpose of helping them in continuing the treatment and meet the high cost of medication.

At present, the company has included its two drugs(Abirapro prescribed for prostate cancer and Evermil, indicated for different cancers) under the scheme.

Sujesh Vasudevan, Glenmark Pharmaceuticals President &Head India Business said that “High drug cost is one of the primary reasons for patients not completing treatment or dropping out of treatment. While Glenmark Oncology supports select needy patients with free drug support, EMI is one step forward to help patients stay on treatment.”

Read EquityPandit’s Nifty Pharma outlook for this week